Survodutide

• Published trial findings, not established product benefits: in the 46-week Phase 2 obesity trial, mean body-weight change at the 4.8 mg target dose was -14.9% versus -2.8% with placebo
• In the peer-reviewed 76-week SYNCHRONIZE-1 report (n=725), the primary treatment-regimen estimand showed mean changes of -12.2% with 3.6 mg, -13.0% with 6.0 mg, and -5.4% with placebo; at least 5% weight reduction occurred in 72.6%, 71.9%, and 46.3%, respectively
• In the 48-week Phase 2 MASH trial, MASH improvement without fibrosis worsening occurred in 47%, 62%, and 43% at the three evaluated doses versus 14% with placebo; fibrosis improvement by at least one stage without MASH worsening occurred in 34%, 36%, and 34% versus 22%
• In SYNCHRONIZE-MASLD, 218 participants were randomized and 216 were treated; under the week-48 efficacy estimand, at least 30% relative liver-fat reduction occurred in 84.2% versus 24.3%, liver fat normalized to below 5% in 61.0% versus 5.7%, and mean body-weight change was -12.2% versus -1.0%
• These indication-, dose-, population-, and estimand-specific results must not be generalized to an RUO product or to individual outcomes.

CAS

2805997-46-8

Formula

C₁₉₂H₂₈₉N₄₇O₆₁

Molecular weight

4231.69 g/mol

Appearance

White lyophilized powder

Purity

≥ 99.0% · target, verify batch COA

Storage

Follow the released-lot COA and supplier instructions. Unless the batch documentation specifies otherwise, keep the sealed lyophilized RUO material desiccated, protected from light, and at or below -20°C; avoid repeated freeze-thaw cycles after reconstitution and establish solution stability in the laboratory's validated protocol. Storage claims for clinical pens or formulated investigational product do not qualify an RUO bulk peptide.

MOQ

1 kit (10 vials) per SKU

Lead time

14–21 days

Survodutide (BI 456906) is an investigational 29-residue, lipidated glucagon-receptor/GLP-1-receptor dual agonist co-developed by Boehringer Ingelheim and Zealand Pharma. The FDA Global Substance Registration System identifies it as UNII 2ALA66NS64, CAS 2805997-46-8, with formula C₁₉₂H₂₈₉N₄₇O₆₁; PubChem assigns CID 168429725. The peptide contains Ac4c at position 2 and a Lys24 side-chain modification that includes a C18 diacid-linked hydrophilic spacer, features designed to resist enzymatic cleavage and prolong exposure through albumin binding. Peer-reviewed Phase 3 publications now include SYNCHRONIZE-1 in adults with obesity or overweight without diabetes and SYNCHRONIZE-MASLD in metabolic dysfunction-associated steatotic liver disease. Other programs, including SYNCHRONIZE-2, SYNCHRONIZE-CVOT, and LIVERAGE, remain under study. The developer reports FDA Fast Track and Breakthrough Therapy designations for non-cirrhotic MASH with F2/F3 fibrosis. Survodutide remains investigational; its safety and efficacy have not been approved for marketing by any regulatory authority.

• Published or registered research areas include obesity or overweight without diabetes (Phase 2 and SYNCHRONIZE-1), obesity with type 2 diabetes (Phase 2 and SYNCHRONIZE-2), metabolic dysfunction-associated steatotic liver disease (SYNCHRONIZE-MASLD), biopsy-confirmed MASH with fibrosis (Phase 2 and LIVERAGE), cardiovascular outcomes (SYNCHRONIZE-CVOT), and pharmacokinetics in people with compensated or decompensated cirrhosis
• Evidence maturity differs by indication: positive peer-reviewed results are available for selected Phase 2 studies, SYNCHRONIZE-1, and SYNCHRONIZE-MASLD, whereas other programs remain ongoing or have published design/baseline information only
• Survodutide is investigational and not approved for marketing.

Survodutide activates both the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R). GLP-1R signaling is associated with reduced appetite, delayed gastric emptying, and glucose-dependent effects on insulin and glucagon, while GCGR signaling can increase energy expenditure and hepatic lipid oxidation. The combined clinical effect remains dose-, population-, and study-dependent. Ac4c at position 2 reduces susceptibility to DPP-4 cleavage, and the Lys24-linked C18 diacid/spacer promotes high albumin binding and an approximately six-day terminal half-life reported in clinical pharmacokinetic studies. Mechanistic and body-composition interpretations remain model- and protocol-dependent and do not establish clinical performance of an RUO lot.

• Safety findings are trial-specific
• In SYNCHRONIZE-1, gastrointestinal adverse events occurred in 80.9% of the 3.6 mg group, 89.7% of the 6.0 mg group, and 47.9% of placebo participants; no deaths occurred during the trial
• In SYNCHRONIZE-MASLD, adverse-event-related treatment discontinuation occurred in 19.9% of survodutide-treated participants versus 4.3% with placebo; mean heart-rate change at week 52 was +3.6 versus +0.8 beats per minute
• That study reported no adjudication-confirmed drug-induced liver injury, acute pancreatitis, pancreatic cancer, or thyroid cancer in the survodutide group, but its authors noted limitations including 48-week duration, two-country recruitment, a predominantly White population, and mostly early or mild-to-moderate fibrosis
• A cirrhosis pharmacokinetic study found broadly similar exposure across hepatic-function groups, but this does not establish general safety or authorize a dose recommendation
• Survodutide remains investigational and an RUO lot is not a finished drug or suitable for human use.

Interactions reported in the literature

• No established combination-use, compatibility, or interaction profile exists for an RUO survodutide material
• In the Phase 2 type 2 diabetes study, semaglutide 1.0 mg served as an open-label comparator rather than a combination treatment, and metformin was allowed as background therapy under protocol-defined conditions
• These observations do not establish compatibility with semaglutide, tirzepatide, insulin, other incretin therapies, glucagon-receptor agonists, or any medication
• Interaction and co-treatment questions require an approved protocol and qualified clinical or institutional oversight; this catalog does not provide medication-management advice.

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

• 10 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

• Require a released-lot COA that identifies the exact peptide form, sequence, theoretical mass, counterion, purity method, water content, and net peptide content
• Confirm identity by orthogonal mass spectrometry rather than HPLC alone
• Match CAS 2805997-46-8, PubChem CID 168429725, formula C₁₉₂H₂₈₉N₄₇O₆₁, and the Lys24 side-chain modification to the supplied form
• Define endotoxin, bioburden, residual-solvent, and solution-stability requirements in the receiving laboratory's validated protocol
• Do not infer sterility, clinical grade, or suitability for human administration from analytical purity.

Follow the released-lot COA and supplier instructions. Unless the batch documentation specifies otherwise, keep the sealed lyophilized RUO material desiccated, protected from light, and at or below -20°C; avoid repeated freeze-thaw cycles after reconstitution and establish solution stability in the laboratory's validated protocol. Storage claims for clinical pens or formulated investigational product do not qualify an RUO bulk peptide.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

• 1) FDA Global Substance Registration System. Survodutide substance record, UNII 2ALA66NS64; CAS 2805997-46-8; formula C₁₉₂H₂₈₉N₄₇O₆₁. PubChem CID 168429725. 2) le Roux CW, et al. Efficacy and safety of survodutide, a glucagon and GLP-1 receptor dual agonist, in people with obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024. PMID 38330987; doi:10.1016/S2213-8587(23)00356-X. 3) Blüher M, et al. BI 456906: dual glucagon/GLP-1 receptor agonist in people with overweight or obesity and type 2 diabetes. Diabetologia. 2023; PMCID PMC10844353. 4) Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024. PMID 38847460; doi:10.1056/NEJMoa2401755. 5) Hohmann N, et al. Efficacy, tolerability and pharmacokinetics of survodutide in people with cirrhosis. J Hepatol. 2024. PMID 38857788; doi:10.1016/j.jhep.2024.06.003. 6) Wharton S, et al. Survodutide for Treatment of Obesity. N Engl J Med. 2026. PMID 42253238; doi:10.1056/NEJMoa2600751; NCT06066515. 7) Newsome PN, et al. Survodutide in metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026. PMID 42252333; doi:10.1038/s41591-026-04479-3; NCT06309992. 8) ClinicalTrials.gov and developer records for SYNCHRONIZE-2, SYNCHRONIZE-CVOT, and LIVERAGE; use current registry status and peer-reviewed results where available rather than promotional or consumer summaries.

1. 01

   Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

   Lancet Diabetes & Endocrinology · 2024 · peer-reviewed original research (randomized controlled trial)

   Open source
2. 02

   A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

   New England Journal of Medicine · 2024 · peer-reviewed original research (randomized controlled trial)

   Open source
3. 03

   Survodutide Once Weekly for the Treatment of Adults with Obesity

   New England Journal of Medicine · 2026 · peer-reviewed original research (randomized controlled trial, phase 3)

   Open source
4. 04

   Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

   Nature Medicine · 2026 · peer-reviewed original research (randomized controlled trial, phase 3)

   Open source
5. 05

   Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)

   Obesity (Silver Spring) · 2025 · peer-reviewed trial-design/rationale publication

   Open source
6. 06

   Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial

   Boehringer Ingelheim (official company website) · 2026 · company press release / official clinical results page

   Open source
7. 07

   Positive data from two Phase III SYNCHRONIZE obesity trials

   Boehringer Ingelheim US (official company website) · 2026 · company press release / official clinical results page

   Open source
8. 08

   Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

   GlobeNewswire (Boehringer Ingelheim official press release) · 2024 · regulatory milestone / company press release

   Open source

• How to read a peptide COA without confusing purity, identity and content
• Peptide purity versus peptide content: a buyer’s method map
• Questions to ask a research peptide supplier before the first purchase order